搜索临床试验以:camrelizumab 联合白蛋白结合型紫杉醇和法米替尼
总计529个结果
-
Fudan University主动,不招人
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.尚未招聘
-
Fondazione Policlinico Universitario Agostino Gemelli...完全的
-
AHS Cancer Control AlbertaCelgene主动,不招人
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.招聘中
-
Atlantic Health SystemCornerstone Pharmaceuticals未知
-
Chinese PLA General Hospital招聘中
-
Ying Lin招聘中Her-2 阴性乳腺癌 | HRR基因突变中国
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing Friendship Hospital 和其他合作者尚未招聘
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen University招聘中
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.招聘中
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.尚未招聘
-
Hebei Medical University尚未招聘
-
Norwegian Breast Cancer Group完全的
-
Verastem, Inc.招聘中转移癌 | 胰腺癌 | 胰腺肿瘤 | KRAS 激活突变 | 胰腺恶性肿瘤美国
-
AstraZeneca完全的晚期或转移性乳腺癌 | ER+ve 晚期或转移性乳腺癌加拿大, 法国, 大韩民国, 捷克语, 秘鲁, 英国, 西班牙, 日本, 墨西哥, 新加坡, 保加利亚
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.未知
-
Zhongshan Hospital Xiamen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.尚未招聘
-
BioNumerik Pharmaceuticals, Inc.Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.完全的
-
Fondazione Italiana Linfomi - ETSRoche Pharma AG尚未招聘
-
Fujian Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.尚未招聘肝转移 | 恶性黑色素瘤
-
Innovent Biologics (Suzhou) Co. Ltd.WuXi CDS Clinical Research (Shanghai) Co.Ltd.完全的
-
Pieris Pharmaceuticals, Inc.主动,不招人
-
Philogen S.p.A.Immatics Biotechnologies GmbH终止
-
Guangdong Association of Clinical Trials尚未招聘